The Oncology Institute, Inc. TOI Clinical trials & other — Total segment amortization
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by The Oncology Institute, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.
The official record: The Oncology Institute, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about The Oncology Institute, Inc.'s clinical trials & other — total segment amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is The Oncology Institute, Inc.'s clinical trials & other — total segment amortization?
- The Oncology Institute, Inc. (TOI) reported clinical trials & other — total segment amortization of $0 in Q1 2026.
- How has The Oncology Institute, Inc.'s clinical trials & other — total segment amortization changed year-over-year?
- The Oncology Institute, Inc.'s clinical trials & other — total segment amortization decreased by 100.0% year-over-year, from $55K to $0.
- What is the long-term trend for The Oncology Institute, Inc.'s clinical trials & other — total segment amortization?
- Over 4 years (2021 to 2025), The Oncology Institute, Inc.'s clinical trials & other — total segment amortization has grown at a -15.0% compound annual growth rate (CAGR), from $211K to $110K.
- What does clinical trials & other — total segment amortization mean?
- This metric measures the systematic allocation of the cost of intangible assets associated with the clinical trials and other business segment over their estimated useful lives. It provides insight into the non-cash expense related to intellectual property, research licenses, or acquired intangible rights specific to this segment.